Expression of nm23-H1 gene product in esophageal squamous cell carcinoma and its association with vessel invasion and survival

Background  

We assessed the nm23-H1 gene product expression and its relationship with lymphatic and blood vessel invasion in patients with esophageal squamous cell carcinoma.     

食管鳞癌nm23-H1蛋白表达及DNA倍体与淋巴结转移关系

目的研究食管鳞癌nm23-H1蛋白表达及DNA倍体状态与区域淋巴结转移的关系.方法应用流式细胞仪检测食管癌患者新鲜手术标本包括食管癌组织(癌)、食管癌旁粘膜(癌旁)、食管正常粘膜(切缘)及食管癌区域淋巴结(淋巴结)中nm23-H1蛋白表达水平及DNA倍体状态.结果无论有、无淋巴结转移,nm23-H1蛋白表达在癌与癌旁、癌与切缘之间差异有显著性(P＜0.05),癌与淋巴结之间差异无显著性(P＞0.05);DNA指数(DI)在癌组织与癌旁、切缘、淋巴结之间比较差异均有显著性(P＜0.05),癌旁、切缘、淋巴结之间DI差异无显著性(P＞0.05);nm23-H1蛋白表达在有、无淋巴结转移两组对应组织间比较差异均有显著性(P＜0.05);两组对应组织比较DI差异无显著性(P＞0.05);DI在不同病理分级间差异有显著性(P＜0.05),DI及nm23-H1蛋白表达在性别、肿瘤部位、病理类型、浸润深度间差异无显著性(P＞0.05).结论nm23-H1蛋白高表达对食管癌转移有一定的抑制作用,结合DNA倍体检测有助于了解食管鳞癌的生物学行为和预后判断.     

Prognostic significance of nm23-H1 expression in oral squamous cell carcinoma

Recent studies indicated nm23-H1 played a role in cancer progression. Therefore, we investigated clinical significance of nm23-H1 expression in oral squamous cell carcinoma (OSCC). In total, 86 OSCC specimens were immunohistochemically stained with nm23-H1-specific monoclonal antibodies. Immunohistochemical staining of nm23-H1 was confirmed by immunoblotting. The relations between nm23-H1 expression and clinicopathologic variables were evaluated by chi(2) analysis. As increased size of primary tumour could escalate metastatic potential and the data of patients at the late T stage might confound statistical analyses, we thus paid special attention to 54 patients at the early T stage of OSCC. Statistical difference of survival was compared by a log-rank test. Immunohistochemically, nm23-H1 expression was detected in 48.8% (42 out of 86) of tumorous specimens. It positively correlated with larger primary tumour size (P=0.03) and inversely with cigarette-smoking habit (P=0.042). In patients at the early T stage, decreased nm23 expression was associated with increased incidence of lymph node metastasis (P=0.004) and indicated poor survival (P=0.014). Tumour nm23-H1 expression is a prognostic factor for predicting better survival in OSCC patients at the early T stage, which may reflect antimetastatic potential of nm23. Therefore, modulation of nm23-H1 expression in cancer cells can provide a novel possibility of improving therapeutic strategy at this stage. In addition, our results further indicated cigarette smoking could aggravate the extent of nm23-H1 expression and possibly disease progression of OSCC patients.     

nm23-H1 expression in squamous cell carcinoma of the head and neck

Archival material from 47 patients with primary squamous cell carcinoma of the head and neck (SCCHN) was studied immunohistochemically for the presence of nm23-H1 protein. Our data indicate that nm23-H1 protein expression is a common event in SCCHN and that there is a trend toward correlation of increased expression of nm23-H1 with increasing tumor size (p = 0.072). The results also show that when adjusting for age and cause of death, there tended to be an inverse relationship between overall survival and the expression of nm23-H1 gene in the primary tumor (p = 0.088).     

The association between nm23 gene expression and survival in patients with sarcomas.

The relationship between the expression of nm23, a putative metastasis-suppressor gene and prognosis was determined for 88 patients with sarcomas. Immunohistochemistry using immunopurified anti-nm23 peptide antibodies was performed and the results of each case graded according to the degree of staining. Univariate and multivariate analyses were carried out to determine the prognostic significance of nm23 staining for sarcoma patients. Expression of nm23 was found to increase in line with metastatic potential in many cases but this did not reach significance for the study as a whole. However, the possibility of nm23 loss occurring in association with metastasis cannot be ruled out in some more aggressive sarcomas, as was demonstrated for six patients with low-scoring, unclassified and synovial sarcomas that had metastasized. The time to metastasis was longer for patients with grade 3 sarcomas (50-75% of tumour cells staining) than similar patients in other staining groups. These results suggest that expression of nm23 genes in sarcomas is variable and has no value as a prognostic indicator for these mesenchymal tumours.     

食管鳞状细胞癌p16和nm23-H1基因蛋白表达及意义

目的 :探讨多肿瘤抑制基因p16蛋白和nm2 3 H1基因蛋白在人食管癌的表达及与肿瘤生物学行为的关系。方法 :应用免疫组织化学方法观察 51例食管鳞状细胞癌及其淋巴结转移癌中p16蛋白的表达 ,结合观察转移抑制基因nm 2 3 H1的表达。结果 :p16在食管鳞状细胞癌中呈低表达 ( 4 5 1% ,2 3/51) ,阳性率显著低于正常食管粘膜及癌旁组织 (P <0 0 1) ,阳性率与分化程度相关 (P <0 0 1) ,Ⅰ级66 7% ( 14/ 2 1) ,Ⅱ级 34 8% ( 8/ 2 5) ,Ⅲ级 14 3% ( 1/ 7) ;与肿瘤浸润、转移无关。nm 2 3 H1的阳性率为60 8% ( 31/ 51) ,与浸润深度呈负相关 (P <0 0 5) ,淋巴结转移癌的阳性率 ( 18 8% ,3/ 16)显著低于食管癌原发灶 (P <0 0 1)。p16与nm 2 3 H1的表达无关。结论 :p16蛋白在食管癌的低表达提示有频发性的p16基因失活 ,且与肿瘤分化有关。nm2 3 H1与食管癌的浸润 ,转移相关。p16和nm 2 3 H1的失活在食管癌的形成及发展中可能起不同的作用     

食管鳞状细胞癌中nm23-H1和p53蛋白表达及其相互关系

目的:探讨食管鳞癌组织中p53和nm23-H1蛋白的表达与癌组织分化浸润转移的关系,以及探讨两者之间的相关性,并进一步分析癌组织中p53和nm23-H1蛋白表达对食管癌患者的预后意义。方法:采用免疫组织化学(S-P法)方法对100例人食管鳞癌组织中的p53和nm23-H1蛋白的表达情况进行检测。结果:100例食管鳞癌组织中,nm23-H1阳性表达者70例(阳性率为70%),p53阳性表达者64例(阳性率为64%)。nm23-H1蛋白表达与食管癌淋巴结转移有关(P<0.025),与食管鳞状细胞癌的分化程度、肿瘤部位、浸润深度、病变长度以及患者性别、年龄无关(P>0.05)。p53蛋白表达与食管鳞状细胞癌的分化程度、浸润深度有关(P<0.05),与食管癌淋巴结转移、肿瘤部位、病变长度、患者性别、年龄无关(P>0.05)。高分化鳞癌组织中p53明显低表达(29.2%);低分化鳞状细胞癌组织中p53表达明显增高(71.4%)。食管外膜受累者p53表达较高(56%);仅发生食管粘膜和(或)粘膜下浸润组的癌组织中未发现有p53蛋白的表达。食管癌组织中nm23-H1蛋白低(高)表达与p53高(低)表达之间有明显相关性(P<0.01)。nm23-H1和p53蛋白表达亦与食管癌的TNM分期密切相关(P<0.05)。食管癌TNM分期越晚,其癌组织中nm23-H1蛋白表达越低,p53蛋白表达越高。结论:nm23-H1基因低表达与p53基因高表达可能在食管鳞状细胞癌浸润转移过程中发挥重要作用。nm23-H1可以作为食管鳞状细胞癌患者预后的基因标记,其蛋白表达产物的检测可以用于患者预后的判断,并为患者治疗方案的制定提供参考。     

p53和nm23-H1蛋白表达与食管癌浸润转移的关系

Objective To study the relationship between expression of p53 and nm23-H1 and differentiation, invasiveness and metastasis in human esophageal carcinoma, and the correlation between expression of p53 and nm23-H1. Methods Expression of p53 and nm23-H1 in 50 patients with squamous cell carcinoma of esophagus was detected by using immuno-histochemical S-P methods. Results 35 cases (70%) and 32 cases (64%) of esophageal squamous cell carcinoma were positive for nm23-H1 protein and p53 protein, respectively. The expression of nm23-H1 was related to lymphatic metastasis (P<0.025), but not related to tumor differentiation, invasiveness, tumor location, tumor length, patient's gender and age (P>0.05). The lymphatic metastasis location positive group had a very lower expression of nm23-H1 and the negative rate was 70.8%, but the negative group had a higher expression and the positive rate was 65.4%. The expression of p53 was related to tumor differentiation and invasiveness (P<0.05), but not related to lymphatic metastasis, tumor location, tumor length, patient's gender and age(P>0.05). Among the three groups, the high differentiation group had the lowest expression of p53 and the positive rate was 29.2%, but the low differentiation group had the highest positive rate (71.4%). As for tumor invasiveness, the group of outer membrane of esophagus infiltrated had the highest p53 protein positive rate (56%), but in the group, of mucous or submucous layer infiltrated p53 protien was not detectable. The low expression of nm23-H1 and the high expression of p53 were also correlated. The expression of nm23-H1 and p53 were both correlated with TNM stage of esophageal carcinoma (P<0.05). The better esophageal carcinomas differentiated, the lower nm23-H1 expressed and higher p53 expressed. Conclusion Low expression of nm23-H1 and high expression of p53 play an important role in the progression of squamous cell carcinoma of esophagus. Nm23-H1 might beta gene markef in the prophecy of patients' prognosis and benefit tumor treatment clinically.     

Expression of nm23-H1 and nm23-H2 protein in endometrial carcinoma.

nm23 gene expression has been shown to be inversely correlated with tumour metastatic potential in some cancers but not in others. Examination was made of the expression of nm23-H1 and nm23-H2 gene products by immunohistochemistry and immunoblotting in 28 endometrial carcinomas. Immunohistochemistry indicated the cytoplasm of cancer cells to be positive, and myometrium and endometrial stromal cells negative, for nm23-H1 and -H2 protein. The staining intensity for these proteins was significantly stronger in well-differentiated adenocarcinomas (G1) than in those moderately differentiated (G2) (P < 0.05). nm23-H1 and -H2 proteins were shown by immunoblotting to be present at significantly higher levels in G1 than in G2 tumours (P < 0.05). Two of eight cases expressed high nm23-H1 and -H2 protein in poorly differentiated adenocarcinomas (G3). In G3 tumours, nm23 expression may be diverse. In this study, the expression of nm23-H1 and -H2 was not correlated with stage, metastasis, tumour size, myometrial invasion, oestrogen receptor, progesterone receptor or menopause. It follows from the findings presented above that the high expression of nm23-H1 and -H2 is positively correlated with histological differentiation.     

食管鳞癌组织LSDl表达与预后相关性分析

目的：研究组蛋白赖氨酸特异性脱甲基酶1（1ysinespecificdemethylase1,LSDl）在食管鳞癌组织中的表达及其与临床病理因素的关系,并探讨其与预后的相关性。方法：收集2005—01—01—2006—12—31在福建省肿瘤医院胸外科接受食管癌三野根治术且术前未接受放疗或化疗的食管鳞癌患者135例。免疫组化检测135例食管鳞癌及其配对癌旁正常食管黏膜组织的LSDl表达水平。运用Y。检验分析肿瘤组织LSDl表达与临床病理因素的关系。运用Kaplan-Meier方法和Log—rank检验分析肿瘤组织LSDl表达与患者术后总生存时间的关系。采用Cox模型对食管癌患者预后相关因素进行多因素回归分析。结果：食管鳞癌组织LSDl强阳性表达率为53．3％,在正常食管黏膜组织中为7．6％,差异有统计学意义,x2=9．016,P=0．002。LSDl高表达与性别（x2=0．396,P=0．546）、年龄（x2=2．530,P=0．123）、T分期（x2=1．264,P=0．286）、淋巴结转移（x2=1．136,P=0．343）、TNM分期（x2=0．396,P=0．546）和分化（x2=0．415,P=0．537）无显著相关性,而与生存时间是否超过5年（x2=6．699,P=0．013）显著相关。Cox多因素回归分析显示,淋巴结转移（p=0．001）、肿瘤浸润深度（P=0．004）和LSDl表达水平（P=0．020）是食管鳞癌患者的独立预后因素。生存分析提示,LSDl强阳性组患者预后明显差于LSDl弱阳性组患者,P=0．008。亚组分析显示,在有淋巴结转移的患者中,肿瘤LSDl强阳性与患者预后相关,P=0．014;而在无淋巴结转移的患者中,LSDl强阳性与预后无显著相关性,P=0373结诊．T-Snl在仓管鳞痛钼织申表达上调．其强阳性表达与不良预后相关。     

CD44v6、EGFR及nm23-H1基因蛋白在食管鳞癌组织中的表达及意义

 目的　探讨食管鳞癌中CD4 4v6、EGFR及nm2 3 H1蛋白表达的意义。方法　应用免疫组化S P法检测 5 0例食管鳞癌中CD4 4v6、EGFR及nm2 3 H1蛋白表达。结果　CD4 4v6、EGFR、nm2 3 H1蛋白表达总阳性率分别 6 4 %、70 %、5 0 % ;显示CD4 4v6及EGFR阳性表达率与食管鳞癌分化程度、浸润深度及淋巴结转移率呈正相关 (P <0 .0 5及P <0 .0 1) ,与患者预后呈负相关 (P <0 .0 0 5 ) ;而nm2 3 H1蛋白表达则与以上两者表达状况相反。结论　同时检测食管鳞癌中CD4 4v6、EGFR及nm2 3 H1基因蛋白表达水平 ,对判断食管鳞癌恶性程度、浸润转移潜能及评估患者预后有一定参考价值。     

NM23-H1 expression of head and neck squamous cell carcinoma in association with the response to cisplatin treatment

We recently reported that low NM23-H1 expression of head and neck squamous cell carcinoma (HNSCC) correlated with poor patients'' prognosis. Growing evidence has indicated that high tumor NM23-H1 expression contributes to a good response to chemotherapy. Therefore, we investigated the role of NM23-H1 in susceptibility of HNSCC cells to cisplatin and its clinical significance, as well as the in vitro study for validation was performed. Using immunohistochemistry, we analyzed NM23-H1 expression in surgical specimens from 46 HNSCC patients with cervical metastases receiving surgery and adjuvant chemoradiotherapy. Low tumor NM23-H1 expression correlated with locoregional recurrence of HNSCC following postoperative cisplatin-basedtherapy (p = 0.056) and poor patient prognosis (p = 0.001). To validate the clinical observation and the effect of NM23-H1 on cisplatin cytotoxicity, we established several stable clones derived from a human HNSCC cell line (SAS) by knockdown and overexpression. Knockdown of NM23-H1 attenuated the chemosensitivity of SAS cells to cisplatin, which was associated with reduced cisplatin-induced S-phase accumulation and downregulation of cyclin E1 and A. Overexpression of NM23-H1 reversed these results, indicating the essential role of NM23-H1 in treatment response to cisplatin. NM23-H1 may participate in HNSCC cell responses to cisplatin and be considered a potential therapeutic target.     

nm23-H1 expression in salivary adenoid cystic carcinoma in relation to metastasis and survival

The expression of nm23-H1, product of putative metastasis suppressor gene, was evaluated immunohistochemically in 31 cases of adenoid cystic carcinoma (ACC) of salivary glands and correlated with their clinicopathologic features. All benign salivary gland tumors of various types, which were used as a non-metastatic control, showed obvious nm23-H1 expression. The immunoreactivity of tumor cells was stronger than that of normal salivary gland components, although the distribution patterns of positive cells considerably varied between tumor types. In ACC, 16 cases (52%) showed the reduction of nm23-H1 immunoreactivity either in positive cell frequency or staining intensity. These cases were referred to as negative cases. The incidence of negative cases was 67% (10/15) and 38% (6/16) of the cases with and without metastasis, respectively. Furthermore, metastatic tumors showed decreased immunoreactivity of this protein compared with their primary tumors. The prognosis of patients with a nm23 negative tumor was generally poorer than that with a positive tumor. These results may suggest that the reduction of nm23-H1 protein has an implication for metastasis of ACC.     

Survivin nm23-H1在非小细胞肺癌中的表达及相关性研究

目的:研究肿瘤相关基因survivin、nm23-H1在非小细胞肺癌﹙NSCLC﹚组织中的表达及相关性.探讨其与临床病理特征之间的关系.方法:采用免疫组化SP 法检测survivin和nm23-H1在52例NSCLC组织、20例对应癌旁组织和15例正常组织中的表达情况.结果:survivin的表达癌组织明显高于癌旁组织的表达,差异具有显著性(P<0.05),正常组织无survivin表达;nm23-H1的表达癌组织明显低于癌旁组织的表达,差异具有显著性(P<0.05);Survivin在NSCLC组织中的表达与年龄、性别、组织类型、淋巴结转移无关(P>0.05), nm23-H1在伴有淋巴结转移的NSCLC组织中表达的阳性率为19.0%(4/21),在未伴有淋巴结转移的NSCLC组织中表达的阳性率为48.4%(15/31),两者差异有显著性;survivin在TNM(Ⅰ+Ⅱ)期NSCLC组织中表达低于在TNM(Ⅲ+Ⅳ)期NSCLC组织中表达;nm23-H1在TNM(Ⅰ+Ⅱ)期NSCLC组织中表达高于在TNM(Ⅲ+Ⅳ)期NSCLC组织中表达,差别有显著意义(P<0.05);survivin在高分化NSCLC中表达低于在低分化NSCLC中表达;nm23-H在高分化NSCLC组织中表达高于在低分化NSCLC组织中表达,差别有显著意义(P<0.05);survivin、nm23-H1在NSCLC中表达负相关(P<0.05).结论:survivin 和nm23-H1 的表达与NSCLC发生、临床进展及预后密切相关.Survivin可以作为NSCLC的早期诊断指标,并可以根据survivin与nm23-H1的联合检测来判断恶性程度及预后.     

食管鳞癌中bcl-2与nm23-h1基因表达情况与纵隔淋巴结转移的相关研究

目的：研究与探讨bcl-2基因与nm23-h1基因在食管鳞状细胞癌中的表达情况及其与纵隔淋巴结转移的关系。方法：采用免疫组化SP法观察了85例食管鳞癌手术切除标本切片中bcl-2和nm23-h1的表达。结果：63．53％（54／85）肿瘤呈bcl-2阳性表达，bcl-2表达与肿瘤淋巴结转移及TNM分期有关（P均〈0．05）。40％（34／85）肿瘤呈nm23阴性表达，nm23-h1阴性表达与肿瘤侵润深度、淋巴结转移、TNM分期有关（P分别为0．032、0．001、0．001）。单因素分析显示：bcl—2基因与nm23-h1基因表达为影响淋巴结转移的主要因素（OR值分别为6．985、0．014，P〈O．001）。而其他临床病理学参数与淋巴结转移之间未见明显相关（P均〉0．05）。bcl-2基因与nm23-h1基因表达之间呈负相关（0=-0．3849，P〈0．05），在促进肿瘤的进展和转移过程中起联合作用。结论：bcl-2基因与nm23-h1基因联合测定是判断食管鳞癌患者淋巴结转移倾向及预后的一个重要手段。     

The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma.

Recently, nm23-H1, an anti-metastasis gene, has been reported to correlate with sensitivity to chemotherapeutic agents including cisplatin in human breast and ovarian carcinoma cells. The aim of this study was to evaluate a role for nm23-H1 in responsiveness to cisplatin-based chemotherapy in patients with oesophageal squamous cell carcinoma (OSCC). The expression of nm23-H1 protein was examined immunohistochemically in 32 eligible patients with OSCC who underwent adjuvant chemotherapy with cisplatin, etoposide, and 5-fluorouracil after tumour resection. Fifteen (46.9%) of 32 patients were positive for nm23-H1 staining and 17 (53.1%) were negative. Both disease-free survival and overall survival rates of nm23-H1-negative patients were significantly shorter than in nm23-H1-positive patients (P < 0.01 for both). There was no significant difference in clinicopathologic characteristics between nm23-H1-positive and nm23-H1-negative groups. Multivariate analysis also showed that nm23-H1 expression was the most significant factor for overall survival of OSCC patients included in this study (P = 0.0007). To further study the role of nm23-H1, a human OSCC cell line (YES-2) was transfected with a plasmid containing a fragment of the nm23-H1 cDNA in an antisense orientation. Reduced expression of nm23-H1 protein in the antisense-transfected (AS) clones was found by Western blot analysis as compared to wild-type YES-2 and YES-2/Neo (clone transfected with the neomycin resistance gene alone). MTT (3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H tetrazolium bromide) assay showed that reduced expression of the nm23-H1 protein in AS clones was consistent with the degree of increased resistance to cisplatin but not etoposide or 5-fluorouracil. These data support the conclusion that reduced expression of nm23-H1 may be associated with resistance to cisplatin, suggesting the value of nm23-H1 expression as a prognostic marker for OSCC patients who are to undergo cisplatin-based chemotherapy.     

Inverse association of nm23-H1 expression by colorectal cancer with liver metastasis.

The expression of nm23-H1 mRNA and protein was studied in colorectal cancers by Northern blotting and immunohistochemistry. All 21 colorectal cancers studied by Northern blotting had increased levels of nm23-H1 mRNA relative to the adjacent normal colonic mucosa. Increased nm23-H1 protein expression was also observed in all 36 colorectal cancer cases including those studied by Northern blotting. There was no significant correlation between nm23-H1 expression and tumour histology, serosal invasion, lymphatic invasion, venous invasion, or lymph node metastasis. However, the expression of both mRNA and protein was significantly lower in tumours associated with liver metastasis than in those without such metastasis. These observations indicate that the nm23 gene may play a role in the suppression of liver metastasis of colorectal cancer.     

nm23-H1 expression in nasopharyngeal carcinoma: correlation with clinical outcome

The expression levels of nm23-H1 mRNA and its protein in human nasopharyngeal carcinoma (NPC) were detected to clarify the relationship between nm23-H1 and metastasis and prognosis of patients with NPC. nm23-H1 mRNA expression in fresh tissues from 78 patients with NPC was investigated by in situ hybridization and RT-PCR. Routine labeling streptavidin-biotin immuno-histochemistry with the nm23-H1 murine monoclonal antibody was employed to study the expression of nm23-H1 protein in paraffin-embedded specimens from 231 patients with NPC treated in our hospital. The clinical pathologic data and results of follow-up were collected. Comparisons between expression of nm23-H1 protein or mRNA and clinical outcome were performed using the χ² test. Multivariate prognostic analyses were performed by the Cox regression model. We found that nm23-H1-negative tumors were associated with a higher incidence of lymph-node metastasis (84.2%) than nm23-H1-positive ones (32.8%, p < 0.01). The distant metastasis and loco-regional recurrence rates in the nm23-H1-negative group were 55.8% and 31.68%, respectively but only 17.2% and 11.5%, respectively, in the nm23-H1-positive group (p < 0.01). A significant association was found between expression of nm23-H1 protein and prognosis (p < 0.01). Expression of nm23-H1 protein indicated favorable prognosis, suggesting that the absence of nm23-H1 protein expression was significantly associated with lymph-node metastasis, recurrence and distant metastasis in NPC. Expression of the nm23-H1 gene may be valuable for assessing the prognosis of NPC. Int. J. Cancer (Pred. Oncol.) 79:596–600, 1998. © 1998 Wiley-Liss, Inc.     

nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma

The role of the nm23 gene in human ovarian cancer is still controversial. We studied the expression of the nm23-H1 gene in 247 human epithelial ovarian carcinomas. The patients were followed-up until their death, or for a minimum of 5 years if they survived. The expression of the gene was studied by means of immunohistochemistry and a semiquantitative scoring system considering the staining intensity and the number of reactive tumour cells. Patients carrying tumours with higher expression scores (4-6 on a scale from 0 to 6) had a significantly lower survival (P = 0.01) than the rest. Further stratified statistical analysis revealed that this effect was mainly attributable to the subgroup of patients with early-stage (I and II), well- and moderately differentiated tumours. In fact, a multivariate analysis carried out for this subset of patients showed nm23-overexpression to be the only significant independent predictor of an ominous prognosis. The association of nm23-overexpression with a worse prognosis was most probably not due to mutation of the nm23 gene, since mutational analysis in 60 tumours by means of single-strand conformational polymorphism and direct sequencing disclosed only one mutation, which was located outside the open reading frame. Our results seem to indicate that nm23 expression is associated with a significantly worse prognosis in early-stage, well-differentiated epithelial ovarian carcinoma, a finding with important clinical implications, considering that many patients with ovarian cancers showing these features do not undergo any further treatment beyond surgical staging. If confirmed, they could help in tailoring the treatment of these patients in the future.     

nm23-H1基因在肺多形性癌组织中的表达及意义

目的　探讨 nm2 3- H1基因表达与肺多形性癌转移及预后的关系。方法　应用免疫组化 S- P法回顾性分析 2 0例肺多形性癌组织中 nm2 3- H1基因表达 ,并结合肺多形性癌的转移、侵袭力、肿块大小及预后进行分析。结果　 nm2 3- H1基因在肺多形性癌中表达阳性率 ,有淋巴结转移组 (2 5 .0 % )低于无淋巴结转移组 (87.5 % ) (P<0 .0 1) ,有侵犯周围组织组 (12 .5 % )低于无侵犯周围组织组 (10 0 % ) (P<0 .0 1) ,肿块直径 >6 cm组 (4 2 .8% )与肿块直径 <6 cm组 (5 0 .0 % ) ,差异无显著性 (P>0 .0 5 )。结论　 nm 2 3- H1基因表达与肺多形性癌有无淋巴结转移、侵袭力强弱关系密切 ,而与肿块大小无关。 nm 2 3- H 1基因高表达预示肺多形性癌转移及侵袭力低 ,预后可能较好